Cannabis oil trial aims to tame seizures in rare genetic disorder

NCT ID NCT07403266

Recruiting now Disease control Sponsor: Oils4Cure Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a full-spectrum cannabis extract (YCJ-01) in 84 people aged 2 to 65 with tuberous sclerosis complex (TSC) whose seizures have not been controlled by standard treatments. Participants will receive either the cannabis extract or a placebo for two months. The study measures whether the extract reduces monthly seizure counts and monitors for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: full-spectrum cannabis extract (YCJ-01)
What this could lead to: If it works, this could offer a new treatment option to reduce seizures in people with tuberous sclerosis complex who have not responded to other therapies.
What could go wrong: This is a Phase 3 trial, but it is still relatively small (84 participants). The cannabis extract may not reduce seizures more than a placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX (TSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberous sclerosis tuberous sclerosis 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBEROUS SCLEROSIS COMPLEX (TSC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Hospital Ruber Internacional
RECRUITING

Madrid, 28034, Spain

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.